Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- Making drug costs more transparent to consumers: a summary for policymakers1
- Manufacturers may need additional guidance to ensure consistent calculations of average sales prices1
- Medicaid's most costly outpatient drugs1
- Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2020 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices1
- Medicare Part B: Medicare represented at least half of the market for 22 of the 84 most expensive drugs in 2015 : report to Congressional requesters1
- Medicare Part D1
- Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters1